GLP-1 Market
LLY $1311.66 ▲ +3.2% NVO $39.63 ▲ +1.5% PFE $30.36 ▲ +1.7% VKTX $25.81 ▼ -2.2% KLRA $13.23 ▲ +2.4% GPCR $22.07 ▲ +0.3% RHHBY $59.11 ▼ -0.0%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/

Company
LG Chem
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 20, 2026

Trial details
  • Completed NCT NCT07396844

    The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers

    Not yet reported LG Chem 28 participants Est. completion 2026-06-26 1 site Stand-alone
    Other conditions: Healthy, Fasting, Fed
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/, Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.